Further, these preclinical data strongly support bringing our findings from the bench to the bedside for relapsed and/or refractory MCL targeting the MMEJ pathway through POLΘ inhibition with or without ATM inhibition. The gene discussed is ATM; the disease is mantle cell lymphoma.